Loading…

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leuke...

Full description

Saved in:
Bibliographic Details
Published in:Blood cancer journal (New York) 2014-08, Vol.4 (8), p.e238-e238
Main Authors: Seymour, J F, Kim, D W, Rubin, E, Haregewoin, A, Clark, J, Watson, P, Hughes, T, Dufva, I, Jimenez, J L, Mahon, F-X, Rousselot, P, Cortes, J, Martinelli, G, Papayannidis, C, Nagler, A, Giles, F J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c446t-602a072e159a66a413cf3f06dcd7de20004cbd790dd92bd854f073a0c213097a3
cites cdi_FETCH-LOGICAL-c446t-602a072e159a66a413cf3f06dcd7de20004cbd790dd92bd854f073a0c213097a3
container_end_page e238
container_issue 8
container_start_page e238
container_title Blood cancer journal (New York)
container_volume 4
creator Seymour, J F
Kim, D W
Rubin, E
Haregewoin, A
Clark, J
Watson, P
Hughes, T
Dufva, I
Jimenez, J L
Mahon, F-X
Rousselot, P
Cortes, J
Martinelli, G
Papayannidis, C
Nagler, A
Giles, F J
description Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation. Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)- or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuous infusion of MK-0457 administered every 14 days at 40 mg/m 2 /h, 32 mg/m 2 /h or 24 mg/m 2 /h. Fifty-two patients (CP, n =15; AP, n =14; BP, n =11; Ph+ ALL, n =12) were treated. Overall, 8% of patients achieved major cytogenetic response; 6% achieved unconfirmed complete or partial response; 39% had no response. Two patients (CP CML) achieved complete hematologic response. No patients with advanced CML or Ph+ ALL achieved major hematologic response. The most common adverse event (AE) was neutropenia (50%). The most common grade 3/4 AEs were neutropenia (46%) and febrile neutropenia (35%). MK-0457 demonstrated minimal efficacy and only at higher, intolerable doses; lower doses were tolerated and no unexpected toxicities were observed. These data will assist in the development of future aurora kinase inhibitors and in the selection of appropriate target patient populations.
doi_str_mv 10.1038/bcj.2014.60
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4219463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4037599671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-602a072e159a66a413cf3f06dcd7de20004cbd790dd92bd854f073a0c213097a3</originalsourceid><addsrcrecordid>eNptkV1rFDEUhoMottReeS8BL-2s-ZyPG2G7qC2uCFKvQybJ7GSdScYkU9lf4181223LFpqbEzgPzzmHF4C3GC0wovXHVm0XBGG2KNELcEoQYwWnNX959D8B5zFuUX68xA1uXoMTwjGpaENOwb8lnHoZDSQwplnvoO_g928FYryC1sFJJmtcivCvTT28XP0slpdreEMxv4bjnKRLUPXBO6vguDOD3xjn5wgHM_82o5VQOp39dpDaDLnKO3r00Y-mmHy0yd4aKNWcDBx249T7dpAxZduD4Q141ckhmvP7egZ-ffl8s7oq1j--Xq-W60IxVqaiRESiihjMG1mWkmGqOtqhUitdaUPy7Uy1umqQ1g1pdc1ZhyoqkSKYoqaS9Ax8OninuR2NVvnoIAcxBTvKsBNeWvG042wvNv5WMIIbVtIseH8vCP7PbGISWz8Hl3cWuKpZzRHne-rDgVLBxxhM9zgBI7EPVORAxT5QUaJMvzte6pF9iC8DFwcg5pbbmHA09Bnff6neq7o</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1784850553</pqid></control><display><type>article</type><title>A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia</title><source>PubMed Central Free</source><source>Publicly Available Content (ProQuest)</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Seymour, J F ; Kim, D W ; Rubin, E ; Haregewoin, A ; Clark, J ; Watson, P ; Hughes, T ; Dufva, I ; Jimenez, J L ; Mahon, F-X ; Rousselot, P ; Cortes, J ; Martinelli, G ; Papayannidis, C ; Nagler, A ; Giles, F J</creator><creatorcontrib>Seymour, J F ; Kim, D W ; Rubin, E ; Haregewoin, A ; Clark, J ; Watson, P ; Hughes, T ; Dufva, I ; Jimenez, J L ; Mahon, F-X ; Rousselot, P ; Cortes, J ; Martinelli, G ; Papayannidis, C ; Nagler, A ; Giles, F J</creatorcontrib><description>Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation. Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)- or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuous infusion of MK-0457 administered every 14 days at 40 mg/m 2 /h, 32 mg/m 2 /h or 24 mg/m 2 /h. Fifty-two patients (CP, n =15; AP, n =14; BP, n =11; Ph+ ALL, n =12) were treated. Overall, 8% of patients achieved major cytogenetic response; 6% achieved unconfirmed complete or partial response; 39% had no response. Two patients (CP CML) achieved complete hematologic response. No patients with advanced CML or Ph+ ALL achieved major hematologic response. The most common adverse event (AE) was neutropenia (50%). The most common grade 3/4 AEs were neutropenia (46%) and febrile neutropenia (35%). MK-0457 demonstrated minimal efficacy and only at higher, intolerable doses; lower doses were tolerated and no unexpected toxicities were observed. These data will assist in the development of future aurora kinase inhibitors and in the selection of appropriate target patient populations.</description><identifier>ISSN: 2044-5385</identifier><identifier>EISSN: 2044-5385</identifier><identifier>DOI: 10.1038/bcj.2014.60</identifier><identifier>PMID: 25127392</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/154/109/1941 ; 692/699/67/1990/283/1896 ; 692/699/67/1990/283/2125 ; Adult ; Aged ; Amino Acid Substitution ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Female ; Fusion Proteins, bcr-abl - genetics ; Hematology ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Male ; Middle Aged ; Mutation, Missense ; Oncology ; Original ; original-article ; Philadelphia Chromosome ; Piperazines - administration &amp; dosage ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics ; Protein Kinase Inhibitors - administration &amp; dosage</subject><ispartof>Blood cancer journal (New York), 2014-08, Vol.4 (8), p.e238-e238</ispartof><rights>The Author(s) 2014</rights><rights>Copyright Nature Publishing Group Aug 2014</rights><rights>Copyright © 2014 Macmillan Publishers Limited 2014 Macmillan Publishers Limited</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-602a072e159a66a413cf3f06dcd7de20004cbd790dd92bd854f073a0c213097a3</citedby><cites>FETCH-LOGICAL-c446t-602a072e159a66a413cf3f06dcd7de20004cbd790dd92bd854f073a0c213097a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1784850553/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1784850553?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25127392$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seymour, J F</creatorcontrib><creatorcontrib>Kim, D W</creatorcontrib><creatorcontrib>Rubin, E</creatorcontrib><creatorcontrib>Haregewoin, A</creatorcontrib><creatorcontrib>Clark, J</creatorcontrib><creatorcontrib>Watson, P</creatorcontrib><creatorcontrib>Hughes, T</creatorcontrib><creatorcontrib>Dufva, I</creatorcontrib><creatorcontrib>Jimenez, J L</creatorcontrib><creatorcontrib>Mahon, F-X</creatorcontrib><creatorcontrib>Rousselot, P</creatorcontrib><creatorcontrib>Cortes, J</creatorcontrib><creatorcontrib>Martinelli, G</creatorcontrib><creatorcontrib>Papayannidis, C</creatorcontrib><creatorcontrib>Nagler, A</creatorcontrib><creatorcontrib>Giles, F J</creatorcontrib><title>A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia</title><title>Blood cancer journal (New York)</title><addtitle>Blood Cancer Journal</addtitle><addtitle>Blood Cancer J</addtitle><description>Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation. Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)- or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuous infusion of MK-0457 administered every 14 days at 40 mg/m 2 /h, 32 mg/m 2 /h or 24 mg/m 2 /h. Fifty-two patients (CP, n =15; AP, n =14; BP, n =11; Ph+ ALL, n =12) were treated. Overall, 8% of patients achieved major cytogenetic response; 6% achieved unconfirmed complete or partial response; 39% had no response. Two patients (CP CML) achieved complete hematologic response. No patients with advanced CML or Ph+ ALL achieved major hematologic response. The most common adverse event (AE) was neutropenia (50%). The most common grade 3/4 AEs were neutropenia (46%) and febrile neutropenia (35%). MK-0457 demonstrated minimal efficacy and only at higher, intolerable doses; lower doses were tolerated and no unexpected toxicities were observed. These data will assist in the development of future aurora kinase inhibitors and in the selection of appropriate target patient populations.</description><subject>631/154/109/1941</subject><subject>692/699/67/1990/283/1896</subject><subject>692/699/67/1990/283/2125</subject><subject>Adult</subject><subject>Aged</subject><subject>Amino Acid Substitution</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Female</subject><subject>Fusion Proteins, bcr-abl - genetics</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation, Missense</subject><subject>Oncology</subject><subject>Original</subject><subject>original-article</subject><subject>Philadelphia Chromosome</subject><subject>Piperazines - administration &amp; dosage</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</subject><subject>Protein Kinase Inhibitors - administration &amp; dosage</subject><issn>2044-5385</issn><issn>2044-5385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkV1rFDEUhoMottReeS8BL-2s-ZyPG2G7qC2uCFKvQybJ7GSdScYkU9lf4181223LFpqbEzgPzzmHF4C3GC0wovXHVm0XBGG2KNELcEoQYwWnNX959D8B5zFuUX68xA1uXoMTwjGpaENOwb8lnHoZDSQwplnvoO_g928FYryC1sFJJmtcivCvTT28XP0slpdreEMxv4bjnKRLUPXBO6vguDOD3xjn5wgHM_82o5VQOp39dpDaDLnKO3r00Y-mmHy0yd4aKNWcDBx249T7dpAxZduD4Q141ckhmvP7egZ-ffl8s7oq1j--Xq-W60IxVqaiRESiihjMG1mWkmGqOtqhUitdaUPy7Uy1umqQ1g1pdc1ZhyoqkSKYoqaS9Ax8OninuR2NVvnoIAcxBTvKsBNeWvG042wvNv5WMIIbVtIseH8vCP7PbGISWz8Hl3cWuKpZzRHne-rDgVLBxxhM9zgBI7EPVORAxT5QUaJMvzte6pF9iC8DFwcg5pbbmHA09Bnff6neq7o</recordid><startdate>20140815</startdate><enddate>20140815</enddate><creator>Seymour, J F</creator><creator>Kim, D W</creator><creator>Rubin, E</creator><creator>Haregewoin, A</creator><creator>Clark, J</creator><creator>Watson, P</creator><creator>Hughes, T</creator><creator>Dufva, I</creator><creator>Jimenez, J L</creator><creator>Mahon, F-X</creator><creator>Rousselot, P</creator><creator>Cortes, J</creator><creator>Martinelli, G</creator><creator>Papayannidis, C</creator><creator>Nagler, A</creator><creator>Giles, F J</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20140815</creationdate><title>A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia</title><author>Seymour, J F ; Kim, D W ; Rubin, E ; Haregewoin, A ; Clark, J ; Watson, P ; Hughes, T ; Dufva, I ; Jimenez, J L ; Mahon, F-X ; Rousselot, P ; Cortes, J ; Martinelli, G ; Papayannidis, C ; Nagler, A ; Giles, F J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-602a072e159a66a413cf3f06dcd7de20004cbd790dd92bd854f073a0c213097a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>631/154/109/1941</topic><topic>692/699/67/1990/283/1896</topic><topic>692/699/67/1990/283/2125</topic><topic>Adult</topic><topic>Aged</topic><topic>Amino Acid Substitution</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Female</topic><topic>Fusion Proteins, bcr-abl - genetics</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation, Missense</topic><topic>Oncology</topic><topic>Original</topic><topic>original-article</topic><topic>Philadelphia Chromosome</topic><topic>Piperazines - administration &amp; dosage</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</topic><topic>Protein Kinase Inhibitors - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seymour, J F</creatorcontrib><creatorcontrib>Kim, D W</creatorcontrib><creatorcontrib>Rubin, E</creatorcontrib><creatorcontrib>Haregewoin, A</creatorcontrib><creatorcontrib>Clark, J</creatorcontrib><creatorcontrib>Watson, P</creatorcontrib><creatorcontrib>Hughes, T</creatorcontrib><creatorcontrib>Dufva, I</creatorcontrib><creatorcontrib>Jimenez, J L</creatorcontrib><creatorcontrib>Mahon, F-X</creatorcontrib><creatorcontrib>Rousselot, P</creatorcontrib><creatorcontrib>Cortes, J</creatorcontrib><creatorcontrib>Martinelli, G</creatorcontrib><creatorcontrib>Papayannidis, C</creatorcontrib><creatorcontrib>Nagler, A</creatorcontrib><creatorcontrib>Giles, F J</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood cancer journal (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seymour, J F</au><au>Kim, D W</au><au>Rubin, E</au><au>Haregewoin, A</au><au>Clark, J</au><au>Watson, P</au><au>Hughes, T</au><au>Dufva, I</au><au>Jimenez, J L</au><au>Mahon, F-X</au><au>Rousselot, P</au><au>Cortes, J</au><au>Martinelli, G</au><au>Papayannidis, C</au><au>Nagler, A</au><au>Giles, F J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia</atitle><jtitle>Blood cancer journal (New York)</jtitle><stitle>Blood Cancer Journal</stitle><addtitle>Blood Cancer J</addtitle><date>2014-08-15</date><risdate>2014</risdate><volume>4</volume><issue>8</issue><spage>e238</spage><epage>e238</epage><pages>e238-e238</pages><issn>2044-5385</issn><eissn>2044-5385</eissn><abstract>Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation. Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)- or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuous infusion of MK-0457 administered every 14 days at 40 mg/m 2 /h, 32 mg/m 2 /h or 24 mg/m 2 /h. Fifty-two patients (CP, n =15; AP, n =14; BP, n =11; Ph+ ALL, n =12) were treated. Overall, 8% of patients achieved major cytogenetic response; 6% achieved unconfirmed complete or partial response; 39% had no response. Two patients (CP CML) achieved complete hematologic response. No patients with advanced CML or Ph+ ALL achieved major hematologic response. The most common adverse event (AE) was neutropenia (50%). The most common grade 3/4 AEs were neutropenia (46%) and febrile neutropenia (35%). MK-0457 demonstrated minimal efficacy and only at higher, intolerable doses; lower doses were tolerated and no unexpected toxicities were observed. These data will assist in the development of future aurora kinase inhibitors and in the selection of appropriate target patient populations.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>25127392</pmid><doi>10.1038/bcj.2014.60</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2044-5385
ispartof Blood cancer journal (New York), 2014-08, Vol.4 (8), p.e238-e238
issn 2044-5385
2044-5385
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4219463
source PubMed Central Free; Publicly Available Content (ProQuest); Springer Nature - nature.com Journals - Fully Open Access
subjects 631/154/109/1941
692/699/67/1990/283/1896
692/699/67/1990/283/2125
Adult
Aged
Amino Acid Substitution
Biomedical and Life Sciences
Biomedicine
Cancer Research
Female
Fusion Proteins, bcr-abl - genetics
Hematology
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
Male
Middle Aged
Mutation, Missense
Oncology
Original
original-article
Philadelphia Chromosome
Piperazines - administration & dosage
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Protein Kinase Inhibitors - administration & dosage
title A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A56%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%202%20study%20of%20MK-0457%20in%20patients%20with%20BCR-ABL%20T315I%20mutant%20chronic%20myelogenous%20leukemia%20and%20philadelphia%20chromosome-positive%20acute%20lymphoblastic%20leukemia&rft.jtitle=Blood%20cancer%20journal%20(New%20York)&rft.au=Seymour,%20J%20F&rft.date=2014-08-15&rft.volume=4&rft.issue=8&rft.spage=e238&rft.epage=e238&rft.pages=e238-e238&rft.issn=2044-5385&rft.eissn=2044-5385&rft_id=info:doi/10.1038/bcj.2014.60&rft_dat=%3Cproquest_pubme%3E4037599671%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-602a072e159a66a413cf3f06dcd7de20004cbd790dd92bd854f073a0c213097a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1784850553&rft_id=info:pmid/25127392&rfr_iscdi=true